Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.

@article{Nicholls2011EfficacyAS,
  title={Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.},
  author={Stephen J Nicholls and Allan Gordon and Jan O. Johansson and Kathy E Wolski and Christie M. Ballantyne and John J. P. Kastelein and Allen J. Taylor and Marilyn R. N. Borgman and Steven Evan Nissen},
  journal={Journal of the American College of Cardiology},
  year={2011},
  volume={57 9},
  pages={1111-9}
}
OBJECTIVES The purpose of this study was to investigate the safety, tolerability, and efficacy of RVX-208, the first oral agent designed to enhance apolipoprotein (apo) A-I synthesis. BACKGROUND No agent that selectively induces synthesis of apoA-I has reached an advanced stage of clinical development. METHODS A total of 299 statin-treated patients with coronary artery disease were treated with placebo or with RVX-208 at a dose of 50, 100, or 150 mg twice daily for 12 weeks. Changes in… CONTINUE READING
40 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport

  • Brewer HB, S Santamarina-Fojo
  • Am J Cardiol 2003;91:3E–11E
  • 2003
Highly Influential
5 Excerpts

High-density lipoprotein particle size and concentration and coronary risk

  • K El Harchaoui, BJ Arsenault, R Franssen
  • Ann Intern Med
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…